Your browser doesn't support javascript.
loading
Influence of Neoadjuvant Immunotherapy-Chemotherapy on Perioperative Outcomes in Locally Advanced Esophageal Adenocarcinoma.
Nevo, Yehonatan; Tankel, James; Zhao, Hedi; Ramirez, Jaime; Cools-Lartigue, Jonathan; Muller, Carmen; Alcindor, Thierry; Ferri, Lorenzo.
Afiliação
  • Nevo Y; Division of Thoracic Surgery, McGill University Health Centre, Montreal, QC, Canada. yoni.nevo@gmail.com.
  • Tankel J; Division of Thoracic Surgery, McGill University Health Centre, Montreal, QC, Canada.
  • Zhao H; Division of Thoracic Surgery, McGill University Health Centre, Montreal, QC, Canada.
  • Ramirez J; Division of Thoracic Surgery, McGill University Health Centre, Montreal, QC, Canada.
  • Cools-Lartigue J; Division of Thoracic Surgery, McGill University Health Centre, Montreal, QC, Canada.
  • Muller C; Division of Thoracic Surgery, McGill University Health Centre, Montreal, QC, Canada.
  • Alcindor T; Department of Oncology, McGill University Health Centre, Montreal, QC, Canada.
  • Ferri L; Division of Thoracic Surgery, McGill University Health Centre, Montreal, QC, Canada.
Ann Surg Oncol ; 31(9): 5666-5673, 2024 Sep.
Article em En | MEDLINE | ID: mdl-38530527
ABSTRACT

BACKGROUND:

This study evaluated the perioperative outcomes for patients who had locally advanced esophageal adenocarcinoma (EAC) treated with neoadjuvant immunotherapy (IO) and chemotherapy versus a matched cohort of patients who received neoadjuvant chemotherapy (NAC) alone.

METHODS:

A single-center non-randomized phase 2 trial was undertaken with locally advanced (cT3-4 and/or N+) EAC, and 49 patients completed neoadjuvant avelumab + docetaxel, cisplatin, 5FU (DCF) and esophagectomy between February 2018 and February 2020. These patients were matched with contemporary patients (January 2018 to June 2020) who met the inclusion criteria but received neoadjuvant chemotherapy alone (NAC) with a comparable docetaxel-based therapy. The postoperative outcomes then were compared between the two groups.

RESULTS:

For this study, 99 patients with locally advanced EAC underwent esophagectomy and met the enrolment criteria. Of these patients, 50 received NAC alone and 49 received IO + NAC. Baseline characteristics such as age, gender, and clinical stage were comparable between the two groups. Operative approach and rate of minimally invasive esophagectomy (~ 60%) were similar in the two groups. For the NAC-alone and IO + NAC groups, the respective overall and major complication rates were similar between the two groups (50% vs. 51% [p = 0.91] and 20% vs. 26% [p = 0.44], respectively), with concordant rates for anastomotic leak (6 [12%] vs. 6 [12%]; p = 0.86) and respiratory complications (13 [26%] vs. 11 [22%]; p = 0.68). The two groups did not differ significantly in terms of hospital length of stay or 30- and 90-day mortality rates.

CONCLUSION:

The addition of immunotherapy to neoadjuvant chemotherapy for locally advanced esophageal adenocarcinoma does not appear to alter perioperative short-term outcomes significantly after esophagectomy.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Esofagectomia / Terapia Neoadjuvante / Docetaxel Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Surg Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Adenocarcinoma / Protocolos de Quimioterapia Combinada Antineoplásica / Esofagectomia / Terapia Neoadjuvante / Docetaxel Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Surg Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Canadá